Publication details for Prof Roy Andrew QuinlanBattaglia, Rachel A, Beltran, Adriana S, Delic, Samed, Dumitru, Raluca, Robinson, Jasmine A, Kabiraj, Parijat, Herring, Laura E, Madden, Victoria J, Ravinder, Namritha, Willems, Erik, Newman, Rhonda A, Quinlan, Roy Andrew, Goldman, James E, Perng, Ming-Der, Inagaki, Masaki & Snider, Natasha T (2019). Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander Disease severity. eLife 8: e47789.
- Publication type: Journal Article
- ISSN/ISBN: 2050-084X (electronic)
- DOI: 10.7554/eLife.47789
- Further publication details on publisher web site
- Durham Research Online (DRO) - may include full text
Author(s) from Durham
Alexander Disease (AxD) is a fatal neurodegenerative disorder caused by mutations in glial fibrillary acidic protein (GFAP), which supports the structural integrity of astrocytes. Over 70 GFAP missense mutations cause AxD, but the mechanism linking different mutations to disease-relevant phenotypes remains unknown. We used AxD patient brain tissue and induced pluripotent stem cell (iPSC)-derived astrocytes to investigate the hypothesis that AxD-causing mutations perturb key post-translational modifications (PTMs) on GFAP. Our findings reveal selective phosphorylation of GFAP-Ser13 in patients who died young, independently of the mutation they carried. AxD iPSC-astrocytes accumulated pSer13-GFAP in cytoplasmic aggregates within deep nuclear invaginations, resembling the hallmark Rosenthal fibers observed in vivo. Ser13 phosphorylation facilitated GFAP aggregation and was associated with increased GFAP proteolysis by caspase-6. Furthermore, caspase-6 was selectively expressed in young AxD patients, and correlated with the presence of cleaved GFAP. We reveal a novel PTM signature linking different GFAP mutations in infantile AxD.